Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients

Part of paid clinical trials in Los Angeles, California.

Sponsor
Baylor Research Institute
Study ID
NCT03383419
Phase
PHASE2
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Epclusa — DRUG
    If and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course.

Study Details

This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).

Key Dates

Start date
Mar 20, 2018
Status verified
Oct 2025
Primary completion
Dec 30, 2026
Completion
Dec 30, 2026

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: Treatment
    Epclusa® will be started within 14 days of quantifiable viremia and continued for 12 weeks. Within 24 hours prior to first-dose of treatment, HCV genotype will be sent from transplant recipient.

Primary Outcome Measure

Sustained virologic response after 12 weeks of treatment [ Time Frame: 12 weeks ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Cedars-Sinai Medical CenterLos AngelesCalifornia90048
Sean Sana
310-248-7129
Evan Kransdorf, MD (PRINCIPAL_INVESTIGATOR)
Duke University Medical CenterDurhamNorth Carolina27705-
Baylor University Medical CenterDallasTexas75246
Aayla Jamil, MBBS MPH
214-820-1675
Robert L Gottlieb, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By condition

Related Studies